Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1760

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Blood (2019) 134 (Supplement_1): 1270.

https://doi.org/10.1182/blood-2019-128967

Published: 2019

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Blood (2019) 134 (Supplement_1): 845.

https://doi.org/10.1182/blood-2019-122802

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1711.

https://doi.org/10.1182/blood-2019-124978

Published: 2019

Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1715.

https://doi.org/10.1182/blood-2019-129141

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD

Blood (2019) 134 (Supplement_1): 1718.

https://doi.org/10.1182/blood-2019-129129

Published: 2019

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

Easix for Prediction of Survival in Myelodysplastic Syndromes

Almuth Maria Anni Merz, MD, Ulrich Germing, MD, Guido Kobbe, MD, Jennifer Kaivers, MD, Anna Jauch, Aleksandar Radujkovic, MD, Manuela Hummel, Axel Benner, Maximilian Merz, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 1722.

https://doi.org/10.1182/blood-2019-122622

Published: 2019

Journal Articles

Quantitative Modeling of Azacitidine Resistance in Patients with Myelodysplastic Syndrome Identifies Distinct Phenotypes of Disease Progression: Evidence for the Presence of a Disease Versus Native Clone Effect

Roman M Shapiro, MD, Adam R Stinchcombe, PhD

Blood (2019) 134 (Supplement_1): 1723.

https://doi.org/10.1182/blood-2019-130332

Published: 2019

Journal Articles

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD

Blood (2019) 134 (Supplement_1): 1726.

https://doi.org/10.1182/blood-2019-126005

Published: 2019

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Leland Metheny, III, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Natalie Scott Callander, MD, Mark Litzow, MD, Partow Kebriaei, MD, Aric C. Hall, MD, Brenda M Sandmaier, MD, Mei-Jie Zhang, Hai-Lin Wang, MPH, Khalid Bo-Subait

Blood (2019) 134 (Supplement_1): 2036.

https://doi.org/10.1182/blood-2019-125946

Published: 2019

Journal Articles

Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Renu Patel

Blood (2019) 134 (Supplement_1): 2184.

https://doi.org/10.1182/blood-2019-122919

Published: 2019

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Journal Articles

Real-World Application of Molecular Genetic Sequencing in the Management of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: The Wisconsin Experience

Lauren Gabriele Banaszak, MD BS, Erica Reinig, MD, Michael Lasarev, MS, Ryan J. Mattison, MD

Blood (2019) 134 (Supplement_1): 2146.

https://doi.org/10.1182/blood-2019-123676

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

NARROW

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Easix for Prediction of Survival in Myelodysplastic Syndromes

Quantitative Modeling of Azacitidine Resistance in Patients with Myelodysplastic Syndrome Identifies Distinct Phenotypes of Disease Progression: Evidence for the Presence of a Disease Versus Native Clone Effect

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Real-World Application of Molecular Genetic Sequencing in the Management of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: The Wisconsin Experience

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only